New Zealand markets open in 8 hours 50 minutes

Agenus Inc. (AGEN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
4.6500-0.2200 (-4.52%)
At close: 04:00PM EDT
4.7300 +0.08 (+1.72%)
Pre-market: 08:08AM EDT
Full screen
Loading interactive chart…
  • Business Wire

    Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024

    LEXINGTON, Mass., September 13, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, presented data today at the European Society for Medical Oncology (ESMO) Congress held in Barcelona, Spain. The data from a Phase 1 study of botensilimab (BOT), an investigational Fc-enhanced CTLA-4 inhibitor, in combination with balstilimab (BAL), an investigational PD-1 antibody, showed clinical activity in patients with refractory sarcomas, a

  • Business Wire

    Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024

    LEXINGTON, Mass., September 09, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that updated data from the clinical trial of botensilimab and balstilimab in refractory sarcomas will be featured in a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress, taking place September 13-17, 2024, in Barcelona, Spain.

  • Business Wire

    Agenus to Participate in September Investor Conferences

    LEXINGTON, Mass., September 03, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Agenus executives, Dr. Garo Armen, Chief Executive Officer, Robin Taylor, Chief Commercial Officer, and Zack Armen, Head of Investor Relations, will participate in the following upcoming investor conferences: